Some important considerations for validation of ligand-binding assays

被引:13
作者
Findlay, John W. A. [1 ]
机构
[1] Gilead Sci Inc, Clin Pharmacol, Durham, NC 27707 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2009年 / 877卷 / 23期
关键词
Non-linear calibration curve; Accuracy; Specificity; Reference standard; Incurred sample re-analysis; Acceptance criteria; Total error; Proteins; Xenobiotics; QUANTITATIVE ANALYTICAL PROCEDURES; BIOANALYTICAL METHODS VALIDATION; SFSTP PROPOSAL; CHROMATOGRAPHIC METHODS; WASHINGTON CONFERENCE; HUMAN PLASMA; LC-MS/MS; IMMUNOASSAY; HARMONIZATION; STRATEGIES;
D O I
10.1016/j.jchromb.2008.10.045
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Calibration curves for ligand-binding assays (LBAs) are inherently non-linear and standard Curve fitting algorithms require careful selection. Reference standards for macromolecule LBAs are more complex than are low-molecular-weight reference standards. Specificity of small molecule LBAs, and accuracy of reported study sample data are easier to assess by cross-validation with a chromatographic method than for macromolecule LBAs. Due to the lack of knowledge of the potential interference of unknown products of catabolism, proteolysis or biotransformation of macromolecules (particularly proteins) in LBAs for the parent molecule, the accuracy of reported concentrations and derived pharmacokinetic data for macromolecules, as determined by LBA, should be viewed with caution. In validation of LBAs, the total error and confidence interval approaches to assessment of the acceptability of an assay for routine implementation for the desired purpose should be given due consideration. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:2191 / 2197
页数:7
相关论文
共 44 条
[1]  
[Anonymous], 1997, STP Pharma Pratiques
[2]   Evaluation of a peptide ELISA for the detection of rituximab in serum [J].
Blasco, H. ;
Lalmanach, G. ;
Godat, E. ;
Maurel, M. C. ;
Canepa, S. ;
Belghazi, A. ;
Paintaud, G. ;
Degenne, D. ;
Chatelut, E. ;
Cartron, G. ;
Le Guellec, C. .
JOURNAL OF IMMUNOLOGICAL METHODS, 2007, 325 (1-2) :127-139
[3]  
Borchardt R.T., 1996, Models for Assessing Drug Absorption and Metabolism
[4]  
BOULANGER B, 2007, AAPS ANN M SAN DEIG
[5]   ASSAYING TUMOR-NECROSIS-FACTOR CONCENTRATIONS IN HUMAN SERUM - A WHO INTERNATIONAL COLLABORATIVE STUDY [J].
DEKOSSODO, S ;
HOUBA, V ;
GRAU, GE ;
WAAGE, A ;
MEAGER, A ;
KRAMER, SM ;
YAMAZAKI, S ;
KWIATKOWSKI, D ;
LAMCHE, H ;
KLEINHAMMER, G ;
EBERLE, W ;
VANDERMEER, JWM ;
BUURMAN, W ;
TEPPO, AM ;
STEPHENS, S .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 182 (01) :107-114
[6]   Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules [J].
DeSilva, B ;
Smith, W ;
Weiner, R ;
Kelley, M ;
Smolec, JM ;
Lee, B ;
Khan, M ;
Tacey, R ;
Hill, H ;
Celniker, A .
PHARMACEUTICAL RESEARCH, 2003, 20 (11) :1885-1900
[7]  
DUDLEY RA, 1985, CLIN CHEM, V31, P1264
[8]   Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma [J].
Ellis, JD ;
Hand, EL ;
Gilbert, JD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1997, 15 (05) :561-569
[9]  
Eskridge KD, 1997, PHARMACOTHERAPY, V17, P497
[10]   Appropriate calibration curve fitting in ligand binding assays [J].
Findlay, John W. A. ;
Dillard, Robert F. .
AAPS JOURNAL, 2007, 9 (02) :E260-E267